The Experimental Drug Development Centre (EDDC) is a national platform for drug discovery and development formed from the integration of three drug discovery and development units, namely, the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC).EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. We work collaboratively with our public sector and industry partners to translate Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions, with a focus on Asian-prevalent diseases. EDDC possesses a full range of capabilities, including assay development, high throughput screening, antibody cloning, medicinal chemistry, biomarker discovery and ADME (Absorption, Distribution, Metabolism and Excretion) & toxicology. These capabilities allow us to identify drug hits and leads as well as companion biomarkers, and to preclinically advance these discoveries in-house. We also have internal expertise to support candidates through first-in-human studies (Phase 1), followed by proof-of-mechanism or proof-of-concept (Phase 2) studies.Our business development and alliance management team identifies and engages academic, clinical, and bio-pharmaceutical industry partners for development and commercialization of innovative assets and platforms, so that we can bring forward medicines that improve healthcare, and generate a return for Singapore to fund future drug discovery research.
The Experimental Drug Development Centre (EDDC) is a national platform for drug discovery and development formed from the integration of three drug discovery and development units, namely, the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC).EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. We work collaboratively with our public sector and industry partners to translate Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions, with a focus on Asian-prevalent diseases. EDDC possesses a full range of capabilities, including assay development, high throughput screening, antibody cloning, medicinal chemistry, biomarker discovery and ADME (Absorption, Distribution, Metabolism and Excretion) & toxicology. These capabilities allow us to identify drug hits and leads as well as companion biomarkers, and to preclinically advance these discoveries in-house. We also have internal expertise to support candidates through first-in-human studies (Phase 1), followed by proof-of-mechanism or proof-of-concept (Phase 2) studies.Our business development and alliance management team identifies and engages academic, clinical, and bio-pharmaceutical industry partners for development and commercialization of innovative assets and platforms, so that we can bring forward medicines that improve healthcare, and generate a return for Singapore to fund future drug discovery research.
The Experimental Drug Development Centre (EDDC) is a national platform for drug discovery and development formed from the integration of three drug discovery and development units, namely, the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC).EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. We work collaboratively with our public sector and industry partners to translate Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions, with a focus on Asian-prevalent diseases. EDDC possesses a full range of capabilities, including assay development, high throughput screening, antibody cloning, medicinal chemistry, biomarker discovery and ADME (Absorption, Distribution, Metabolism and Excretion) & toxicology. These capabilities allow us to identify drug hits and leads as well as companion biomarkers, and to preclinically advance these discoveries in-house. We also have internal expertise to support candidates through first-in-human studies (Phase 1), followed by proof-of-mechanism or proof-of-concept (Phase 2) studies.Our business development and alliance management team identifies and engages academic, clinical, and bio-pharmaceutical industry partners for development and commercialization of innovative assets and platforms, so that we can bring forward medicines that improve healthcare, and generate a return for Singapore to fund future drug discovery research.